Gimv backs Eurocept

The capital injection will be used by Eurocept to enter new markets in neighbouring countries, both through organic growth and acquisitions. The company will also strengthen its position in its existing market in the Netherlands.

Eurocept has already begun its acquisitive growth strategy, having acquired Danish pharmaceutical company NordMedica earlier this year.

Gimv partly invested via its Gimv Health & Care Fund, which was launched in February 2013 with a €200m target and expects to hold its first formal close in the first quarter of 2014. The fund's first investment took place at the end of November, when Gimv and UI Gestion acquired Almaviva Santé from 21 Partners.

Company
Founded in 2001, Eurocept is headquartered in Ankeveen and currently employs 130 staff. The company recorded turnover of €147m in 2012.

The Eurocept group comprises Eurocept Pharmaceuticals and Eurocept Homecare. Its pharmaceuticals division markets and sells speciality medicines for the anaesthetics, psychiatry, urology, paediatrics and infectious diseases fields.

The company's homecare division provides medical homecare services and outpatient medical technology for medicine and food administration. Its services are designed to allow doctors to stay up-to-date on outpatients' medical status through the use of a care information system and an electronic patient and prescription file.

People
Mike van Woensel is the CEO and founder of Eurocept. Elderd Land is a partner at Gimv for its health & care practice.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Expansion
• Healthcare
• Netherlands
• Gimv